Ontology highlight
ABSTRACT: Purpose
Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL-GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM.Methods
We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions of AXL and GAS6 were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes.Results
The expression of AXL was positively associated with GAS6 expression (P?ConclusionsAXL-GAS6 co-expression represents a potential independent prognostic biomarker for survival outcome in NSCLC BM patients.
SUBMITTER: Wu X
PROVIDER: S-EPMC5599460 | biostudies-literature | 2017 Oct
REPOSITORIES: biostudies-literature
Wu Xiaoliang X Ma Wenjuan W Zhou Qianghua Q Yan Haijuan H Lim Zuan-Fu ZF Huang Mayan M Deng Chuangzhong C Yu Xingsu X Su Huifang H Komo Satoshi S Yang Haixia H Zhang Xinke X Wen Sijin S Zhang Zhenfeng Z Ma Patrick C PC
Journal of cancer research and clinical oncology 20170527 10
<h4>Purpose</h4>Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL-GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM.<h4>Methods</h4>We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions o ...[more]